Dana-Farber News shared a post on X:
“At ASCO26 Dana-Farber‘s Dr. Sara Tolaney presented a subgroup analysis of the ASCENT-04 study based on biomarkers.
Across all subgroups, patients who received sacituzumab govitecan plus pembro as 1st line therapy had longer PFS compared to standandard therapy.”
Other articles about Dr. Tolaney on OncoDaily.